Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Beneficial organisms react differently to parasite drug

14.04.2014

The drug ivermectin is used around the world to combat parasites in humans and animals. The active ingredient is also known to harm dung-degrading beneficial organisms. An international research team headed up by evolutionary biologists at the University of Zurich have now demonstrated that certain dung organisms react more sensitively to ivermectin than previously assumed. Hence there is a need for more sophisticated field tests.

The substance ivermectin has been used for more than thirty years all over the world to combat parasites like roundworms, lice and mites in humans, livestock and pets. The active ingredient belongs to the chemical group of avermectins, which generally disrupt cell transport and thus attack pests.

When ivermectin is excreted in the faeces of treated animals, at overly high doses it also harms dung-degrading beneficial insects like dung beetles and dung flies. This impairs the functioning of the ecosystem. In extreme cases the dung is not decomposed and the pasture is destroyed.

Sensitivity to ivermectin varies considerably
Since 2000 public regulators in many countries therefore mandate standardised safety tests for the use of avermectin derivatives. An international research team headed up by Wolf Blanckenhorn, an evolutionary biologist at the University of Zurich, has now shown that the safety tests used today are not able to sufficiently prevent environmental damage. Even closely related dung organisms react with varying degrees of sensitivity to the same veterinary pharmaceutical.

Blanckenhorn and his colleagues examined 23 species of sepsid flies that typically live in cow dung. “The individual species vary by a factor of 500 in their sensitivity to ivermectin”, comments the evolutionary biologist. The standardised safety tests typically performed in toxicology in the laboratory today are based on single, arbitrarily selected dung organisms.

“There is a considerable risk that the more sensitive species will continue to be harmed by ivermectin and that important ecosystem functions will suffer long-term damage as a consequence”, says Blanckenhorn. To prevent this, safety tests should be extended at least to include a representative selection of all dung-degrading organisms, if not the entire community. “Clearly, these tests would massively increase the costs of the authorisation process for new drugs, and investigators would have to possess specialised biological expertise”, comments the biologist. For that reason a field test should be developed based on a genetic method of species identification, so-called DNA barcoding.

Evolutionary findings
With their study the authors further confirmed that in the course of evolution, as a consequence of pre-existing genetic modifications, first the sensitivity of moulting animals and later the non-sensitivity of particular species groups to avermectins has developed, long before any contact with the drug. Hence, their work also validates the still disputed molecular genetic classification of roundworms (nematodes) and arthropods as moulting animals, as only they are sensitive to avermectins.


The drug Ivermectin
Ivermectin was discovered in Japan in the late 1970s. Since then it has improved the quality of life of millions of people particularly in the tropics: ocular onchocerciasis, scabies and threadworms in the intestines can be successfully treated thanks to Ivermectin. Ivermectin is likewise used in animal husbandry across the globe.

Further reading:
N. Puniamoorthy, M. A. Schäfer, J. Römbke, R. Meier, and W. U. Blanckenhorn. Ivermectin sensitivity is an ancient trait affecting all ecdysozoa but shows phylogenetic clustering among sepsid flies. Evolutionary Applications, April 14, 2014. doi: 10.1111/eva.12152

W. U. Blanckenhorn, N. Puniamoorthy, M. A. Schäfer, A. Scheffczy, and J. Römbke. Standardized laboratory tests with 21 species of temperate and tropical sepsid flies confirm their suitability as bioassays of pharmaceutical residues (ivermectin) in cattle dung. Ecotoxicology and Environmental Safety. March 2013. doi: 10.1016/j.ecoenv.2012.10.020


Contacts:
Prof. Dr. Wolf U. Blanckenhorn
Institute of Evolutionary Biology and Environmental Studies
University of Zurich
Tel. +41 44 635 47 55
Email: wolf.blanckenhorn@ieu.uzh.ch

Weitere Informationen:

http://www.mediadesk.uzh.ch

Nathalie Huber | Universität Zürich

Further reports about: DNA Environmental Evolutionary Ivermectin animals damage ecosystem species

More articles from Life Sciences:

nachricht Multi-institutional collaboration uncovers how molecular machines assemble
02.12.2016 | Salk Institute

nachricht Fertilized egg cells trigger and monitor loss of sperm’s epigenetic memory
02.12.2016 | IMBA - Institut für Molekulare Biotechnologie der Österreichischen Akademie der Wissenschaften GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>